Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 10

Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymph...

A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).

Visit website

Immunotherapy Expert Puts Fresh Focus on AEs

  Oct 15 2020 Tagged ICI, toxicity

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Visit website
Immunotherapy Web Featured Images

Enroll in the newly launched 'Processes in CAR-T' course on the EHA Campus

EHA has just launched the third CAR-T course within its EHA immunotherapy program. Reviewed by Professor Ulrich Jäger from Univ. Klinik Innere Medizin I Medizinische Universität Wien, this course addresses processes involved in the manufacture of CAR T-cells from apheresis to treatment, as well as the role of different team members including pharmacists and nurses. It also includes considerations specific to pediatric patients. This module is freely accessible and part of an eight-course program covering all aspects of CAR-T.

Visit website
Immunotherapy Web Featured Images 7

EBMT 2020 | NK-CAR immunotherapy: the next steps

  Oct 13 2020 Tagged NK-CAR

Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, discusses the next steps with respect to NK-CAR immunotherapy, highlighting a multicenter Phase II study and issues for future studies.

Visit website
Immunotherapy Web Featured Images 8

COMy 2020 | The future of immunotherapies for multiple myeloma

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the future of multiple myeloma treatment.

Visit website
ImmunotherapyWebsite Images Featured 34

NextGen CARs: the race is on

In this issue of Blood, Tong et al present the preclinical and clinical development of an optimized, bivalent tandem CD20/CD19 chimeric antigen receptor (CAR) construct (see figure). Preclinically, they demonstrated dual-antigen specificity, enhanced immune synapse formation, and superior antitumor activity in vitro and in vivo in a murine xenograft model compared with alternative constructs generated from the same 2 single-chain variable fragment (scFv) regions derived from Leu-16 (anti-CD20) and FMC63 (anti-CD19) murine monoclonal antibodie.

Visit website

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...

Human brain mural cells, essential for blood-brain barrier integrity, express CD19 and can then be potential off-tumor target for CD19-directed therapies, including CAR-T cells, suggesting a mechanism for associated neurotoxicity.
Visit website

Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial upda...

  Oct 01 2020 Tagged CAR-T

Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is a popular form of cell therapy, specifically immunotherapy, that can use a patient’s own altered immune cells to fight cancer.

Visit website
ImmunotherapyWebsite Images Featured 35

Exploring Targeted and CAR T-Cell Therapies on the Horizon for MCL

  Sep 25 2020 Tagged CAR-T, MCL, NHL

Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.

Visit website
nature research1

Building better CAR-T therapies

  Sep 23 2020 Tagged CAR-T

The success of chimeric antigen receptor T-cell (CAR-T) therapy has electrified the oncology field. Many specialists gush about its promise. But most people with cancers that the therapy could treat do not currently benefit from it.

Visit website